Evidence map›Paper›PMID 40372095›Full record

ArticleAntimicrobial agents and chemotherapy2025

Meredith A Hackel, James A Karlowsky, Daniel F Sahm, Joshua M West, Nicole E Scangarella-Oman

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04020341 phase3completednot on this map

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

TypeinterventionalSponsorGlaxoSmithKlineRan2019 to 2022Enrolled1,531ConditionsUrinary Tract InfectionsArmsGepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
NCT04187144 phase3completednot on this map

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

TypeinterventionalSponsorGlaxoSmithKlineRan2020 to 2022Enrolled1,606ConditionsUrinary Tract InfectionsArmsGepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meredith A HackelIHMA, Schaumburg, Illinois, USA.ORCID 0000-0003-3339-2701
James A KarlowskyIHMA, Schaumburg, Illinois, USA.
Daniel F SahmIHMA, Schaumburg, Illinois, USA.
Joshua M WestGSK, Collegeville, Pennsylvania, USA.
Nicole E Scangarella-OmanGSK, Collegeville, Pennsylvania, USA.ORCID 0000-0003-4211-8261

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication through a distinct binding site and unique mechanism of action, providing well-balanced inhibition of two different type II topoisomerase enzymes for most uropathogens. Phase III clinical trials, NCT04020341 (EAGLE-2) and NCT04187144 (EAGLE-3), showed gepotidacin to be non-inferior and superior, respectively, to nitrofurantoin for the treatment of patients with uncomplicated urinary tract infections (uUTIs). To better define gepotidacin

Indexed as

AcenaphthenesAnti-Bacterial AgentsEnterobacteriaceaeEnterococcus faecalisHeterocyclic Compounds, 3-RingStaphylococcus saprophyticusUrinary Tract InfectionsClinical Trials as TopicHumansMicrobial Sensitivity TestsAcenaphthenesAnti-Bacterial AgentsgepotidacinHeterocyclic Compounds, 3-Ringgepotidacintriazaacenaphthylenetype II topoisomerase inhibitorurinary tract infections

Identifiers

PMID40372095
PMCPMC12135502

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.